LamassuBioTech

Accelerating treatment, means saving more lives. At Lamassu, our team is driven by a passion to treat patients like family.

[LamassuBioTech @LamassuBioTech]

Learn more and sign up at https://t.co/pP7XTBlc2u.

#pancreatitis #PetsofFacebook #VeterinaryCare #veterinarymedicine #pethealth #dogs

[LamassuBioTech @LamassuBioTech]

Has your dog stopped eating? Lethargic? Appears to be in pain? Canine acute pancreatitis is a life-threatening condition that effects thousands of dogs each year, especially schnauzers, terriers, and cocker spaniels. Right now, there is no effective treatment.

[LamassuBioTech @LamassuBioTech]

But if your dog is suffering from acute pancreatitis, they may be eligible to participate in a groundbreaking clinical trial being administered by veterinarians at @OSUVetCollege.

[LamassuBioTech @LamassuBioTech]

Be sure to catch @LamassuBiotech CEO Dr. Gabi Hanna’s panel discussion on the integration of biotechnology and digital platforms to create smarter, more personalized therapies and diagnostics during the @C3Summit Sunnyvale Davos of Healthcare Summit on Monday, April 27.

Interested in connecting with Dr. Hanna during the summit? Email [email protected].

#Biotech #Innovation #Healthcare #DrugDevelopment #MedicalResearch #Oncology #ClinicalTrials #C3Sunnyvale

[LamassuBioTech @LamassuBioTech]

Full article: https://t.co/lMPSuD6nIn

[LamassuBioTech @LamassuBioTech]

@CrainsCleveland Business: 𝐅𝐨𝐫𝐦𝐞𝐫 𝐅𝐃𝐀 𝐥𝐞𝐚𝐝𝐞𝐫 𝐚𝐩𝐩𝐨𝐢𝐧𝐭𝐞𝐝 𝐭𝐨 𝐋𝐚𝐦𝐚𝐬𝐬𝐮 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐛𝐨𝐚𝐫𝐝 𝐨𝐟 𝐝𝐢𝐫𝐞𝐜𝐭𝐨𝐫𝐬

[LamassuBioTech @LamassuBioTech]

“Lamassu’s team has demonstrated significant growth potential and a strong commitment to a rigorous scientific process,” @SteveFDA said in an emailed statement to Crain’s. “It is always a pleasure to work with people who share your values and your commitment to bringing transformative medicine from the lab to the bedside.”

[LamassuBioTech @LamassuBioTech]

#LamassuBiotech #StephenHahn #FDA #Oncology #DrugDevelopment #Biotech #MedicalResearch

[LamassuBioTech @LamassuBioTech]

With more than three decades of experience working in the field of medical oncology and radiation oncology, the 24th Commissioner of Food and Drugs, Dr. @SteveFDA, has established himself as a national leader in healthcare and a distinguished physician.

[LamassuBioTech @LamassuBioTech]

Full announcement: https://t.co/qdvk4TjoL5

[LamassuBioTech @LamassuBioTech]

Full announcement: https://t.co/qdvk4TjoL5

#LamassuBiotech #StephenHahn #FDA #Oncology #DrugDevelopment #Biotech #MedicalResearch

[LamassuBioTech @LamassuBioTech]

With more than three decades of experience working in the field of medical oncology and radiation oncology, the 24th Commissioner of Food and Drugs, Dr. @SteveFDA, has established himself as a national leader in healthcare and a distinguished physician.

[LamassuBioTech @LamassuBioTech]

As the newest member of @LamassuBioTech's Board of Directors, his expertise will assist our team of physician-scientists as we advance our genetically targeted therapy, SA53, which could be transformative in treating upwards of 50% of all cancer cases including those that currently lack effective treatments.

[LamassuBioTech @LamassuBioTech]

🩸 𝐂𝐑𝐈𝐒𝐏𝐑-𝐂𝐚𝐬𝟏𝟐𝐚 𝐆𝐞𝐧𝐞 𝐄𝐝𝐢𝐭𝐢𝐧𝐠 𝐨𝐟 𝐇𝐁𝐆𝟏 𝐚𝐧𝐝 𝐇𝐁𝐆𝟐 𝐏𝐫𝐨𝐦𝐨𝐭𝐞𝐫𝐬 𝐭𝐨 𝐓𝐫𝐞𝐚𝐭 β-𝐓𝐡𝐚𝐥𝐚𝐬𝐬𝐞𝐦𝐢𝐚
Dr. Hanna was the second author on a paper that reviewed a phase 1–2, multicenter, open-label, single-group study of reni-cel in participants 18 to 35 years of age with transfusion-dependent β-thalassemia. The participants received myeloablative conditioning with busulfan before reni-cel infusion.
Nine participants with transfusion-dependent β-thalassemia (four β0/β0 or β0/β0-like and five non–β0/β0 genotypes) received reni-cel and were included in the analysis...All the participants had neutrophil and platelet engraftment by 42 days after infusion.
🔗 https://t.co/R9IwAnyiqq

[LamassuBioTech @LamassuBioTech]

Congratulations to our co-founder @RabiHannaMD, chairman of Pediatric Oncology at @ClevelandClinic, who has published two articles in the @NEJM. Dr. Hanna is an internationally recognized clinical researcher in the field of transplant and gene therapy.

[LamassuBioTech @LamassuBioTech]

🧬 𝐂𝐑𝐈𝐒𝐏𝐑-𝐂𝐚𝐬𝟏𝟐𝐚 𝐆𝐞𝐧𝐞 𝐄𝐝𝐢𝐭𝐢𝐧𝐠 𝐨𝐟 𝐇𝐁𝐆𝟏 𝐚𝐧𝐝 𝐇𝐁𝐆𝟐 𝐏𝐫𝐨𝐦𝐨𝐭𝐞𝐫𝐬 𝐭𝐨 𝐓𝐫𝐞𝐚𝐭 𝐒𝐢𝐜𝐤𝐥𝐞 𝐂𝐞𝐥𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞
Dr. Hanna is the lead author in this multi-center first-in-human gene editing therapy using CRISPR/Cas12 to treat patients with severe sickle cell disease. Treatment with reni-cel led to normalization of the total hemoglobin level and an increase in the percentage of fetal hemoglobin, with no vaso-occlusive events occurring in 27 of 28 patients after infusion.
🔗  https://t.co/rHnxokxPQE

[LamassuBioTech @LamassuBioTech]

#BIOPartnering #Biotech #Cancer #Innovation #Oncology

[LamassuBioTech @LamassuBioTech]

Success comes from having a sound understanding of the industry's landscape and what differentiates your company from your competitors. That was the message from biotech leaders during this week's "Catalyzing Cancer Innovation" panel discussion, hosted by @IAmBiotech's BIOPartnering™.

[LamassuBioTech @LamassuBioTech]

Lamassu BioTech CEO Gabi Hanna MD shared his insights on the challenges and opportunities for companies looking for success in 2026 alongside @rodmrenshaw Senior Biotechnology Analyst @MichaelGKingJr, Bantam Pharmaceutical CEO @MyRxDx, @CreatvMicroTech, Inc. CBO Ron Baker, and Oncode Accelerator Business Development Manager Federica Frati.